Loading stock data…
$21.51-1.74 (-7.48%)
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
Faeth Therapeutics, Inc. in the Healthcare sector is trading at $21.51 with a market capitalization of $891M. Wall Street consensus targets $56.67 (12 analysts), implying a +163.4% move over the next 12 months. The stock is currently 49% below its 52-week high of $42.14, remaining 12.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.39M↑ | -$170.63M↓ | -$4.96M↓ | -$4.85M↑ | -$5.21M |
| Net Income | -$16.01M↑ | -$170.24M↓ | -$4.72M↓ | -$4.57M↑ | -$4.94M |
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in develop...